WHO WE ARE
Allterum Therapeutics, Inc., is a biopharmaceutical company targeting the IL-7 pathway for the treatment of IL-7R expressing cancers. Allterum was founded in 2018 by Fannin Innovation Studio in Houston, TX.



OUR FOCUS
Why Allterum Therapeutics
Our Partnerships & Collaborators

``I am excited to work with Allterum to develop a much-needed option for the treatment of children with T-cell ALL.``
Eric Schafer, M.D., M.H.S.
Assist. Professor, Pediatrics-Oncology | Texas Children's Hospital & Baylor College of Medicine
”After years of searching for a way to help those kids who have no effective treatment for their leukemia, I’m thrilled to see Allterum take our antibody into the clinic.”
Scott Durum, Ph.D.
Inventor | Cytokine and Immunity Section | National Cancer Institute


Allterum is a Fannin Innovation Studio company.
Fannin Innovation Studio is Houston's most active early-stage life sciences development group with the primary focus being on development of early stage assets, in partnership with our academic collaborators. The studio’s assests include internally developed assets like Brevitest and in-licensed assets from academic institutions including local Houstonian institutions such as MD Anderson Cancer Center, Baylor College of Medicine, Rice University, Houston Methodist, Texas A&M, Texas Children’s, University of Texas, and University of Houston.
STAY UP TO DATE
News
Anticancer Antibody Receives First Funds for Trial in Leukemia Patients
NCI at Frederick – March 19, 2019
ALLTERUM THERAPEUTICS
Advancing an innovative solution for a critical and unmet medical need